Mok TS, Kim D, Wu Y, et al. Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014. ESMO 2017, abstract LBA50.
Eigenschappen PET-tracers onderzocht: meerwaarde klinische toepassing 18F-FES bij ER+ mammacarcinoom
jan 2024 | Borstkanker